Abstract
Elizabethkingia meningoseptica is an opportunistic pathogen increasingly reported as hospital-acquired infection. Here, we report a series of cases of eight patients with invasive E. meningoseptica infections over a period of 27 months in a tertiary teaching hospital from South India. Age range was 45 days to 84 years, median 66 years, with male preponderance. Associated risk factors included recent hospitalization with surgeries, diabetes mellitus, renal failure, mechanically ventilated, and central line. All isolates were susceptible to minocycline. Combination therapy with ciprofloxacin and piperacillin tazobactam was most common. Six recovered and two patients were lost to follow-up.
How to cite this article
Ganesan V, Sundaramurthy R. Elizabethkingia meningoseptica Infections: A Case Series from a Tertiary Hospital in South Tamil Nadu. Indian J Crit Care Med 2022;26(8):958–960.
Keywords: Elizabethkingia meningoseptica, Empirical antibiotic therapy, Intensive care unit
Introduction
Despite ubiquitous presence in hospital environment, E. meningoseptica is overlooked or misidentified as pseudomonas-like organisms in laboratories without trained microbiologists and automated identification system. Prolonged hospitalization, broad spectrum antibiotics, and central line catheter are some of the significant risk factors. In this report, we describe case series of eight invasive E. meningoseptica infections between January 2019 to March 2021 in a tertiary teaching hospital from South Tamil Nadu.
Case Description
Patients’ Characteristics
During the study period, eight patients were identified. Table 1 shows the demographic details, risk factors, and clinical outcome of these patients. Age range was 45 days to 84 years. Associated risk factors included the recent hospitalization with surgeries (5/8) diabetes mellitus (5/8), renal failure (4/8), mechanically ventilation (5/8), and central line (1/8). A case of extreme preterm twin baby with prolonged intensive care unit (ICU) stay had prior blood cultures at different time periods growing multidrug organisms including carbapenem-resistant Escherichia coli, A. baumanii (sensitive only to colistin) and Sphingomonas paucimobilis. Median days of ICU stay prior to bacteremia was 9.5 days (range: 6–48 days). Six acquired infection in the ICU, and two from the hospital ward and dialysis unit each. Cases were reported sporadically without clusters of infection.
Table 1.
Clinical characteristics of the patients
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | |
|---|---|---|---|---|---|---|---|---|
| Age | 79 | 40 | 64 | 75 | 1 | 68 | 22 | 84 |
| Gender | M | M | M | F | M | M | M | M |
| Culture positive | November 2018 | December 2018 | January 2019 | July 2019 | September 2019 | December 2019 | January 2021 | February 2021 |
| Diagnosis | Metabolic encephalopathy | Acute cerebrovascular accident with left hemiparesis | Right foot first metatarsal osteomyelitis/triple vessel disease/bilateral pleural effusion | Acute pulmonary thromboembolism/pneumonitis | Extreme preterm baby | Diabetic foot ulcer with cellulitis | CAPD peritonitis | Large bowel obstruction with sigmoid volvulus, chronic kidney disease/septic shock |
| Recent hospitalization and procedures | Yes, below knee amputation done 2 weeks back | Right frontotemporoparietal decompressive craniectomy and tracheostomy done a week back | Wound debridement and removal of remnant bone done a week back | Laparoscopy assisted vaginal hysterectomy with bilateral salpingo oophorectomy done a week back | Left below knee amputation | Emergency laparotomy with sigmoid colon resection and descending colostomy done 2 weeks back and Blood culture, Klebsiella pneumoniae (CRE) | ||
| ICU stay | Specialty ICU | Neurology ICU | Specialty stepdown ICU | No, Medical ward | Neonatal ICU | Respiratory ICU | No, Surgery ward | Surgical ICU |
| Duration of hospitalization | 10 days | 40 days | 25 days | 2 days | 102 days | 26 days | 14 days | 41 days |
| Diabetes | Yes | Yes | Yes | No | No | Yes | Yes | No |
| Mechanical ventilation | No | Yes | No | No | Yes | Yes | Yes | Yes |
| Central line | No | Yes | No | No | Yes | Yes | No | Yes |
| Number of ICU days prior to bacteremia | 6 | 9 | 10 days | No | 48 days | 22 days | No | 21 |
| Renal failure | No | No | Yes | No | No | Yes | Yes | Yes |
| Treatment | Ciprofloxacin | Meropenem, piptaz | Piptaz, ciprofloxacin | Meropenem, levofloxacin | Piptaz, meropenem | Ciprofloxacin, cotrimoxazole | Intraperitoneal ciprofloxacin for | Piptaz, meropenem |
| Duration of therapy | 9 days | 9 days | 8 days | 5 days | 10 days | 7 days | 14 days | 8 days |
| Microbiological clearance | Yes | Yes | No | Yes | Yes | No | Yes | No |
| Outcome | Survived | Survived | AMA | Survived | Survived | AMA | Survived | Died |
AMA, against medical advice; CAPD, continuous ambulatory peritoneal dialysis; CRE, carbapenem-resistant enterobacteriaceae
Antimicrobial Susceptibility
All isolates were susceptible to minocycline, and varied susceptibility to piperacillin tazobactam (25%) trimethoprim/sulfamethoxazole (37%), and fluoroquinolones (ciprofloxacin 50%, levofloxacin 50%).
Therapeutic Regimens and Outcome
Most commonly, the combination therapy with ciprofloxacin and piperacillin tazobactam was used.
Mortality and Morbidity
Six survived, five of whom achieved microbiological clearance. Two patients were lost to follow-up.
Discussion
Main finding in the study is prior surgical procedure followed by empirical antibiotic therapy was a major predisposing factor for this infection. Intensive care unit stay, medical devices such as central line and ventilator along comorbid conditions such as diabetes mellitus and renal disorder were also potential risk factors. There was no remarkable change in the antimicrobiological susceptibility over 2.5-year period with good susceptibility to minocycline and ciprofloxacin unlike other studies from India.1,2
The above findings implicate that strict infection control measures to be followed rigorously in ICUs and other high-risk areas. Bundle care implementation and audit to be performed in patients on devices. In addition, hospitals should have a properly defined antibiotic stewardship programme with implementation of antibiotic policy followed by periodic antibiotic prescription audit.
Despite the steadily increasing infection in the recent times with a worldwide geographical distribution, it is highly unfortunate that many clinicians are still unaware of this organism. In India, most of the case reports and series are from few large medical centers with well-equipped laboratories. 2–4
Notable limitations include retrospective design of the study, with few cases. Vitek 2 System with limited Elizabethkingia species in its database has poor concordance of species identification in comparison with 16S ribosomal RNA sequencing, only 24.5–26.5%.5 Also as reported by Lau et al., almost all E. anophelis species were misidentified as E. meningoseptica by Vitek 2.6 The species identification was not confirmed by 16SrRNA sequencing in the study.
Highlights
Prior surgical procedure followed by empirical antibiotic therapy was a major predisposing factor for this infection. There was no remarkable change in the antimicrobiological susceptibility over 2.5-year period with good susceptibility to minocycline and ciprofloxacin.
Orcid
Vithiya Ganesan https://orcid.org/0000-0003-0949-2841
Raja Sundaramurthy https://orcid.org/0000-0001-9867-9784
Footnotes
Source of support: Nil
Conflict of interest: None
References
- 1.Singh S, Sahu C, Patel SS, Singh S, Ghoshal U. Clinical profile, susceptibility patterns, speciation and follow up of infections by Elizabethkingia species: study on a rare nosocomial pathogen from an intensive care unit of north India. New Microbes New Infect. 2020;38:100798. doi: 10.1016/j.nmni.2020.100798. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Ghafur A, Vidyalakshmi PR, Priyadarshini K, Easow JM, Raj R, Raja T. Elizabethkingia meningoseptica bacteremia in immunocompromised hosts: The first case series from India. South Asian J Cancer. 2013;2(4):211–215. doi: 10.4103/2278-330X.119912. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Ratnamani MS, Rao R. Elizabethkingia meningoseptica: Emerging nosocomial pathogen in bedside hemodialysis patients. Indian J Crit Care Med. 2013;17(5):304–307. doi: 10.4103/0972-5229.120323. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Govindaswamy A, Bajpai V, Trikha V, Mittal S, Malhotra R, Mathur P. Multidrug resistant Elizabethkingia meningoseptica bacteremia: experience from a level 1 trauma centre in India. Intractable Rare Dis Res. 2018;7(3):172–176. doi: 10.5582/irdr.2018.01077. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Lin JN, Lai CH, Yang CH, Huang YH, Lin HF, Lin HH. Comparison of four automated microbiology systems with 16SrRNAgene sequencing for identification of Chryseobacterium and Elizabethkingia species. Sci Rep. 2017;7(1):13824. doi: 10.1038/s41598-017-14244-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Lau SKP, Chow WN, Foo CH, Curreem SOT, Lo GCS, Teng JLL, et al. Elizabethkingia anophelis bacteremia is associated with clinically significant infections and high mortality. Sci Rep. 2016;6:26045. doi: 10.1038/srep26045. [DOI] [PMC free article] [PubMed] [Google Scholar]
